Login | Register | Forgot your password? | Contact | Español |
Email: Password:

Medwave se preocupa por su privacidad y la seguridad de sus datos personales.
Para poder enviarle a su dirección de correo electrónico su contraseña, es necesario que ingrese su e-mail.


Letters to the editor
Medwave 2018 Mar-Apr;18(2):e7193 doi: 10.5867/medwave.2018.02.7193
Comments on Alegría and Irarrázaval (2017): Is diacerein an alternative for the treatment of osteoarthritis?
Burkhard Leeb
References | Related | Download PDF |
To Download PDF must login.
Print | A(+) A(-) | Easy read

Dear editor:

During my last literature search on Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA), I came across the Friendly Summary of Body of Evidence using Epistemonikos (FRISBEE) by Alegría and Irarrázaval [1]. Although I found the format of this review on diacerein convenient to read and therefore efficient, I felt that I should provide complementary information and correct one of the assumptions regarding the registration status of diacerein in Europe as I consider them essential for decision-making.

In 2012, following the evaluation of data resulting from pharmacovigilance activities, the French Medicine Agency (ANSM) requested a recommendation on the benefit-risk balance of diacerein-containing products by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA). I have been involved in the safety-related referral procedure as an expert witness representing the company TRB Chemedica. Therefore, please let me take the freedom to clarify the sequence of events.

After the Pharmacovigilance Risk Assessment Committee had initially recommended to suspend the marketing authorisation of diacerein in 2013 [2], additional risk management measures were presented by the marketing authorisation holders in order to reduce the risk of severe diarrhoea and hepatotoxicity associated with the use of the drug. Subsequently, after having performed a re-examination in 2014, the Pharmacovigilance Risk Assessment Committee concluded that the benefit-risk balance of diacerein remained positive in the approved indications [3]. The European Medicines Agency endorsed the Pharmacovigilance Risk Assessment Committee recommendations and therefore, the marketing authorisation of diacerein had never been withdrawn nor suspended in Europe. Thereafter, the referral procedure was underlined by an independent experts’ review [4] and a position paper by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) [5]. The latter considered diacerein as an interesting option for treating osteoarthritis and positioned it as a first-line pharmacological background therapy, particularly for osteoarthritis patients with comorbidities contraindicating the use of non-steroidal anti-inflammatory drugs or paracetamol.

Another aspect that deserves emphasis is that diacerein is a SYSADOA with an onset of action at two to four weeks, which becomes significant after four to six weeks [6],[7]. As a result, specifying the time point at which pain and functionality improvements are evaluated would make the message of this review more accurate.

Furthermore, I take the opportunity of this letter to draw your attention to an inconsistency between the text and the FRISBEE table; certainty of the evidence is considered moderate for pain and low for functionality in the summary of findings (page 2 of the PDF version), while it is the opposite in the subsequent table (page 3 of the PDF version).

Finally, I would like to point out that the two clinical trials qualified as ongoing by the authors cannot be regarded as susceptible to modify the current evidence. The first one was conducted in patients with hand osteoarthritis and assessed the efficacy of diacerein versus placebo on pain at one month as primary endpoint, that is a time point too early to expect efficacy of the drug [8]. The second one is an ongoing clinical trial (clinicaltrials.gov NCT02688400) evaluating diacerein versus celecoxib. It will therefore not influence the conclusions of this summary, as it takes into account randomised placebo-controlled clinical trials exclusively.

Notes

Declaration of competing interest
Dr. Leeb represented TRB Chemedica as an expert witness during the referral procedure of the Committee for Pharmacovigilance Risk Assessment in 2013-2014.

Funding
The author states that there were no external sources of funding.

Licencia Creative Commons Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

 

Author: Burkhard Leeb[1,2]

Affiliation:
[1] Second Department of Medicine, Competence Centre for Rheumatology Lower Austria, Federal State Clinical Center Stockerau, Landstrasse 18, 2000 Stockerau, Austria
[2] Private office: A-2020 Hollabrunn, Babogasse 20

E-mail: leeb.rheuma@aon.at

Author address:
[1] Landstrasse 18 2000
Stockerau
Austria

Citation: Leeb B. Comments on Alegría and Irarrázaval (2017): Is diacerein an alternative for the treatment of osteoarthritis?. Medwave 2018 Mar-Apr;18(2):e7193 doi: 10.5867/medwave.2018.02.7193

Submission date: 21/2/2018

Acceptance date: 7/3/2018

Publication date: 12/4/2018

Origin: not requested

Type of review: reviewed by one external peer reviewer, double-blind

PubMed record

Comments (0)

We are pleased to have your comment on one of our articles. Your comment will be published as soon as it is posted. However, Medwave reserves the right to remove it later if the editors consider your comment to be: offensive in some sense, irrelevant, trivial, contains grammatical mistakes, contains political harangues, appears to be advertising, contains data from a particular person or suggests the need for changes in practice in terms of diagnostic, preventive or therapeutic interventions, if that evidence has not previously been published in a peer-reviewed journal.

No comments on this article.


To comment please log in

Medwave provides HTML and PDF download counts as well as other harvested interaction metrics.

There may be a 48-hour delay for most recent metrics to be posted.

  1. Alegría A, Irarrázaval S. Is diacerein an alternative for the treatment of osteoarthritis? Medwave 2017 Sep-Oct; 17(8):e7041 | CrossRef | PubMed |
  2. PRAC recommends suspension of diacerein-containing medicines. London, UK: European Medicines Agency (EMA); 2013 [on line]. | Link |
  3. Assessment report for diacerein containing medicinal products. London, UK: European Medicines Agency (EMA); 2014 [on line]. | Link |
  4. Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf. 2015;38(3):245-52. | CrossRef | PubMed |
  5. Pavelka K, Bruyere O, Cooper C, Kanis JA, Leeb BF, Maheu E, et al. Diacerein: Benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging. 2016;33(2):75-85. | CrossRef | PubMed |
  6. Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994;37(4):529-36. | PubMed |
  7. Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43(10):2339-48. | CrossRef | PubMed |
  8. Shin K, Kim JW, Moon KW, Yang JA, Lee EY, Song YW, et al. The efficacy of diacerein in hand osteoarthritis: a double-blind, randomized, placebo-controlled study. Clin Ther. 2013;35(4):431-9. | CrossRef | PubMed |
Alegría A, Irarrázaval S. Is diacerein an alternative for the treatment of osteoarthritis? Medwave 2017 Sep-Oct; 17(8):e7041 | CrossRef | PubMed |

PRAC recommends suspension of diacerein-containing medicines. London, UK: European Medicines Agency (EMA); 2013 [on line]. | Link |

Assessment report for diacerein containing medicinal products. London, UK: European Medicines Agency (EMA); 2014 [on line]. | Link |

Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf. 2015;38(3):245-52. | CrossRef | PubMed |

Pavelka K, Bruyere O, Cooper C, Kanis JA, Leeb BF, Maheu E, et al. Diacerein: Benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging. 2016;33(2):75-85. | CrossRef | PubMed |

Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994;37(4):529-36. | PubMed |

Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43(10):2339-48. | CrossRef | PubMed |

Shin K, Kim JW, Moon KW, Yang JA, Lee EY, Song YW, et al. The efficacy of diacerein in hand osteoarthritis: a double-blind, randomized, placebo-controlled study. Clin Ther. 2013;35(4):431-9. | CrossRef | PubMed |

Diacerein and arthrosis treatment
Sebastián Irarrázaval, Anselmo Ignacio Alegría Mejías, Gonzalo Bravo Soto, Gabriel Rada (Chile)
Medwave 2018 Mar-Apr;18(2):e7202